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Abstract
Despite key advances in the clinical management of life-threatening ventricular arrhythmias, 
culminating with the development of implantable cardioverter-defibrillators and catheter ablation 
techniques, pharmacologic/biologic therapeutics have lagged behind. The fundamental issue is 
that biological targets are molecular factors. Diseases, however, represent emergent properties at 
the scale of the organism that result from dynamic interactions between multiple constantly 
changing molecular factors. For a pharmacologic/biologic therapy to be effective, it must target 
the dynamic processes that underlie the disease. Here we propose a classification of ventricular 
arrhythmias that is based on our current understanding of the dynamics occurring at the 
subcellular, cellular, tissue and organism scales, which cause arrhythmias by simultaneously 
generating arrhythmia triggers and exacerbating tissue vulnerability. The goal is to create a 
framework that systematically links these key dynamic factors together with fixed factors 
(structural and electrophysiological heterogeneity) synergistically promoting electrical dispersion 
and increased arrhythmia risk to molecular factors that can serve as biological targets. We classify 
ventricular arrhythmias into three primary dynamic categories related generally to unstable Ca 
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cycling, reduced repolarization, and excess repolarization, respectively. The clinical syndromes, 
arrhythmia mechanisms, dynamic factors and what is known about their molecular counterparts 
are discussed. Based on this framework, we propose a computational-experimental strategy for 
exploring the links between molecular factors, fixed factors and dynamic factors that underlie life-
threatening ventricular arrhythmias. The ultimate objective is to facilitate drug development by 
creating an in silico platform to evaluate and predict comprehensively how molecular 
interventions affect not only a single targeted arrhythmia, but all primary arrhythmia dynamics 
categories as well as normal cardiac excitation-contraction coupling.
Keywords
Nonlinear dynamics; fibrillation; reentry; repolarization reserve; Ca signaling; sudden cardiac 
death; cardiac electrophysiology
1. Introduction
With the advent in the 1940’s and 1950’s of intracellular microelectrode recordings and the 
development in subsequent decades of sophisticated arrhythmia mapping and imaging 
techniques, followed by the blossoming of molecular ion channel biophysics and 
computational biology, a wealth of information about arrhythmia mechanisms at the 
molecular, cellular, organ and organism scales has come to light [1– 6]. Based on this 
research, major advances in arrhythmia treatment have occurred over the past century, 
culminating with the development of surgical and catheter ablation techniques and 
implantable cardioverter-defibrillators (ICDs). Pharmacologic/biologic approaches to treat 
arrhythmias, however, have lagged behind. Well-designed clinical trials, such as CAST [7] 
and SWORD [8], revealed that promising agents that were effective at suppressing one 
arrhythmia mechanism proved to be proarrhythmic by exacerbating other mechanisms. As a 
result, the enthusiasm of the pharmaceutical industry for antiarrhythmic drug development 
has been severely curtailed. Yet the need is clearly there. Ablation is curative for some 
arrhythmias, but others do not have discrete anatomical structures to target. Device therapy 
is also not ideal, since ICDs terminate arrhythmias effectively, but do not prevent them. 
Moreover, 80% of patients who will die suddenly each year do not meet clinical indications 
(i.e. low ejection fraction or prior documented arrhythmia history) for implanting an ICD 
[9]. Of the ones who do, only 1 of 5 ICDs implanted will actually deliver a life-saving shock 
due to the difficulty in predicting which patients are at the greatest risk [10].
Why has the development of effective antiarrhythmic drugs been so frustrating?
The generic challenge in controlling or curing any disease pharmacologically is that drugs 
target molecules, but diseases occur at the organism scale, and the relationship between the 
behavior of a molecule and the behavior of an organism is hardly straightforward. In the 
case of arrhythmias, electrophysiological properties that determine the likelihood of an 
arrhythmia at the tissue level are not directly controlled in a straightforward way by single 
molecules. Rather, very complex nonlinear interactions between many molecules first 
integrate to produce the electrophysiological properties at the level of the cell, including the 
action potential (AP), Ca cycling features, automaticity, early (EAD) and delayed (DAD) 
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afterdepolarizations, excitability and refractoriness, etc. These cellular electrophysiological 
factors next integrate, again in complex nonlinear ways, to generate the tissue 
electrophysiological properties, including excitability characteristics, conduction properties, 
dispersion of refractoriness, electrical alternans and a variety of other factors impacting the 
initiation and maintenance of cardiac arrhythmias. Meanwhile, other organ systems in the 
body are constantly dynamically modulating these factors at the molecular, cellular and 
organ scales through autonomic tone, electrolyte balance, various endocrine functions, etc. 
Given the complexity of the system, predicting how modifying a single target molecule will 
impact the behavior of the overall system is a daunting task. Despite this complexity, 
however, successful precedents exist. For example, beta blockers targeting the beta 
adrenergic receptor, and drugs inhibiting angiotensin-converting enzyme (ACE) and 
antagonizing the hormone aldosterone have been proven to reduce the incidence of sudden 
cardiac death in large cohorts of patients with heart failure and ischemic heart disease [11]. 
Unfortunately, we have been much less successful with drugs targeting the ion channels that 
directly influence cardiac electrophysiological properties, possibly because available pre-
clinical experimental and clinical arrhythmia induction paradigms incompletely recapitulate 
clinical arrhythmias.
Can this impasse be broken? In our view, to make substantive progress will require a 
comprehensive analysis linking the function of molecules, the material entities such as ion 
channels or receptors that can be targeted by drugs or biologics, to electrophysiological 
factors that determine arrhythmia risk at the organism scale. This is an inherently multiscale 
problem which requires linking molecular factors first to electrophysiological and structural 
factors at the subcellular scale (e.g. Ca cycling properties), then to factors at the cellular 
scale (e.g. action potential properties), next to factors at the tissue scale (e.g. conduction 
properties), and finally factors to the organism scale (e.g. autonomic and metabolic 
properties) [6]. An advantage of the arrhythmia field, compared to many other disease areas, 
is that we already have a fairly detailed understanding of the electrophysiological and 
structural factors at the subcellular, cellular, organ and organism levels that promote 
arrhythmias. What is lacking is an integrated framework for evaluating and predicting how 
the behaviors of proteins at the molecular scale are linked to the relevant 
electrophysiological and structural factors promoting arrhythmias at the subcellular/cellular/
organ/organism scales. Too often antiarrhythmic drug development strategies have focused 
on one arrhythmia mechanism without considering, in any systematic way, how the drug 
may impact other arrhythmia mechanisms. For example, the CAST study [7] evaluating Na 
channel blockers was based on the premise that suppressing premature ventricular 
complexes (PVCs), the triggers that initiate reentry, should decrease the incidence of 
reentrant ventricular tachycardia (VT) and fibrillation (VF). This was a very reasonable 
hypothesis, but failed to take into account the effects of Na channel blockers on the tissue 
substrate. We know now that Na channel blockers increase the vulnerability of the tissue to 
initiation of reentry. Thus, if the PVC frequency is reduced by a factor of five, but 
vulnerability is concomitantly increased by a factor of ten, the net effect is to double the 
incidence of reentrant arrhythmias. Similarly, the SWORD trial [8] evaluating the K channel 
blocker d-sotalol was based on the premise that prolonging the refractory period would 
suppress reentrant arrhythmias by eliminating excitable gaps in reentry circuits, but failed to 
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take into account the pro-arrhythmic effects of K channel blockers on a different 
mechanism, namely Torsades de Pointes (TdP).
The goal of this perspective is to take stock of our current understanding of the molecular, 
electrophysiological and structural factors that underlie various mechanisms of ventricular 
arrhythmias, and begin to organize this information into a conceptual framework that will 
link molecular behaviors to the subcellular/cellular/organ/organism scale behaviors 
underlying ventricular arrhythmias. The ultimate objective is to utilize this framework to 
evaluate systematically, through combined computational and experimental approaches, 
how potential molecular targets impact not just a single arrhythmia mechanism, but all 
major mechanisms that are clinically relevant to ventricular arrhythmias. Even if our 
understanding of arrhythmia dynamics is currently incomplete, the proposed framework will 
serve as a starting point that can be further developed to incorporate new information as it 
becomes available.
2. Rationale
The rationale for developing a dynamics-based classification of ventricular arrhythmias is to 
link molecular factors to the dynamic factors controlling arrhythmias at the supra-molecular 
scales. Molecular factors are the material biological entities, e.g. druggable or genetically-
modifiable proteins like ion channels, transporters, receptors, transcription factors or their 
post-translational modification sites, as well as nucleotides, lipids or carbohydrates, etc., that 
can be directly targeted to modify behavior in a desired fashion. Arrhythmias, however, are 
not molecules, but behaviors of an integrated dynamical system, namely the excitable 
medium of cardiac tissue, whose behavior is governed by dynamic factors [12]. Dynamics 
refers to processes that change in time and/or space. Dynamic factors refer to the functional 
electrophysiological properties that are not actual material entities, like molecules, but 
represent the aggregate behavior of many interacting material entities. For example, the 
cardiac AP is a phenomenological descriptor of the change of voltage in a myocyte that 
arises from the aggregate behavior of a large number of interacting ion channels/
transporters. A drug does not interact directly with the AP to modify its properties. A drug 
can only physically interact with another molecule, such as an ion channel/transporter or 
signaling protein, whose interaction with other molecules then influences the AP. Moreover, 
a given property of the AP, such as its refractory period, is not uniquely specified by a single 
combination of ion channel/transporter properties. There are literally billions of 
combinations of ion channel/transporter properties that can produce a nearly identical AP 
duration (APD) or refractory period [13, 14].
In addition to molecular and dynamic factors, a third category also plays a vital role in 
arrhythmogenesis, which we call fixed factors. Fixed factors include structural and 
electrophysiological tissue heterogeneities, such as fibrosis, scars and other anatomic 
obstacles, transmural and apex-to-base AP gradients and electrical ion channel remodeling 
(including gap junction remodeling). These pre-existing tissue heterogeneities create 
dispersion of refractoriness and excitability, which play critical roles in arrhythmogenesis. In 
our view, however, fixed factors do not directly cause ventricular arrhythmias – rather, they 
increase the probability that dynamic factors will initiate arrhythmias by generating triggers 
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and exacerbating tissue heterogeneity. In other words, the fixed factors and dynamic factors 
interact synergistically to lower the threshold of dynamic instability required for arrhythmias 
to emerge.
Fig. 1A summarizes schematically the relationship between molecular factors and the 
dynamic factors and fixed factors that promote arrhythmias, and also makes an important 
distinction – that it is possible to understand the cause of an arrhythmia without 
understanding the mechanism. For example, a genetic mutation in an ion channel protein 
(channelopathy) can cause, unequivocally, a long QT syndrome. However, identification of 
the abnormal protein does not, by itself, provide direct information about the mechanism 
(Fig. 1A). Rather, the mechanism is governed by dynamic factors and fixed factors that link 
the abnormal protein function at the molecular scale to the arrhythmia syndrome at the 
organism scale.
3. Dynamics-based Classification of Arrhythmias
Traditionally, arrhythmias are often classified by mechanism: reentry, triggered activity or 
automaticity. In the ventricles, reentry can take several forms [6]: 1) anatomic reentry 
around an obstacle (such as a scar) manifesting as monomorphic VT ; 2) functional reentry 
due to a stable rotor (spiral/scroll wave reentry), also manifesting as monomorphic VT; 3) 
reentry due to a meandering rotor manifesting as polymorphic VT or TdP; 4) multiple 
wavelet VF due to rotor (spiral/scroll wave) breakup; 5) mother rotor VF due to a fast stable 
rotor with peripheral wavebreaks (fibrillatory conduction block) in surrounding tissue. 
Triggered activity is caused by EADs or DADs, and typically manifests as PVCs or 
monomorphic or polymorphic VT. Automaticity is due to spontaneous diastolic 
depolarization, which is generally slower and manifests as PVCs and idioventricular 
rhythms. Ventricular arrhythmias can be nonsustained or sustained, purely focal or purely 
reentrant or involve a mixture of focal and reentrant mechanisms. In addition, reentry which 
is inherently nonsustained can be constantly reinitiated by focal activations (mixed focal-
reentrant VF). In this scenario, the rapid rates during reentry also promote additional triggers 
(via Ca overload), creating a positive feedback loop that sustains the arrhythmia [15].
The lessons from the CAST study [7] and SWORD trial [8] suggest that antiarrhythmic 
strategies focused solely on suppressing triggers (CAST) or preventing reentry (SWORD) 
are not likely to be successful. Both factors must be taken into account concomitantly. PVCs 
are generally benign if the tissue substrate is not in a state vulnerable to reentry, i.e. if 
electrical dispersion is low. Conversely, PVCs only become dangerous when electrical 
dispersion is high, enhancing the risk of reentry. The highest risk of arrhythmias arises when 
dynamic factors, interacting with fixed factors, simultaneously promote the emergence of 
triggers while enhancing electrical dispersion in the tissue (Fig. 1B)
Accordingly, the goal of a dynamics-based classification of ventricular arrhythmias is to 
place the primary focus on the trigger-tissue substrate interactions – that is, to base the 
classification on the conditions in which the underlying dynamics promote the emergence of 
triggers and electrical dispersion simultaneously. As illustrated in Fig. 1B, the basic 
premises are: 1) Arrhythmias arise acutely from interactions between a trigger and a 
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vulnerable tissue substrate, made vulnerable by a combination of dynamic and fixed factors 
promoting electrical dispersion; 2) The interactions between triggers and substrate 
vulnerability are dynamic and interdependent, both acutely and chronically; 3) The episodic 
nature of arrhythmias indicates that fixed factors causing electrical dispersion, such as 
anatomical structures, scars, fibrosis, etc., do not directly cause arrhythmias, but rather 
sensitize the heart to arrhythmia episodes by lowering the threshold of dynamic instability 
required for arrhythmias to emerge.
Based on these premises, Table 1 presents a proposed dynamics-based classification of 
ventricular arrhythmias summarizing how the dynamic factors at the cellular, tissue and 
organism scales relate to arrhythmia risk at the organ scale. In this classification, the major 
clinically relevant ventricular arrhythmias fall into three broad categories, in which the 
primary dynamic instability promoting arrhythmias is related to 1) unstable Ca cycling, 2) 
reduced repolarization, or 3) excess repolarization. Each category specifies the relevant rare 
and common clinical diseases, arrhythmia mechanisms, cellular and tissue dynamics and the 
key dynamic factors controlling them that can serve as targets to prevent arrhythmias. The 
final row in Table 1 suggests potential molecular factors, still largely speculative at this 
point, that might be targeted biologically to regulate the key dynamic factors/targets. Each 
category is discussed in detail below.
3.1 Arrhythmias Related to Unstable Ca Cycling
Clinical settings—The prototype in this arrhythmia dynamics category is CPVT [16, 17], 
in which mutations to the ryanodine receptor (RyR) and/or its associated sarcoplasmic 
reticulum (SR) proteins, such as calsequestrin, cause RyRs to become overly sensitive to Ca, 
especially when SR Ca stores are potentiated by catecholamine stimulation. Ca cycling 
instabilities are also an important component promoting arrhythmias in heart failure, in 
which RyR Ca sensitivity is increased by chronic adrenergic and Ca-calmodulin kinase II 
(CaMKII) activation, in addition to other changes [18, 19]. Acute ischemia also alters Ca 
cycling by direct and indirect effects of high energy phosphate depletion and metabolite 
accumulation on the function of ion channels/transporters in the sarcolemma and SR.
Arrhythmia mechanisms—The major triggers are DADs, which can induce focal 
ventricular tachycardia (monomorphic, polymorphic or bidirectional VT) due to DAD-
mediated triggered activity [20, 21], or initiate reentry degenerating to multiple wavelet or 
mother rotor VF. Substrate vulnerability is also increased by spatially discordant APD and 
Ca alternans causing dispersion of refractoriness, and subthreshold DADs causing dispersion 
of excitability.
Dynamic mechanisms—Altered Ca cycling under these conditions makes ventricular 
myocytes susceptible to spontaneous SR Ca release from regions of the subcellular Ca 
release unit network, which propagates through the network regeneratively as a Ca wave. 
The resulting elevation in intracellular Ca is sensed by Ca-sensitive inward currents, 
primarily the Na-Ca exchange current (INCX). When Ca waves occur during diastole, the 
activation of depolarizing inward current causes DADs, which, if they reach the threshold 
for Na current (INa) activation, can elicit triggered activity from the myocyte. For DADs to 
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elicit a PVC or triggered activity in tissue, however, a large number of myocytes (up to 
hundreds of thousands in well-coupled three-dimensional (3D) tissue [22]) must develop Ca 
waves synchronously to overcome the source-sink (loading) effect of adjacent myocytes 
without Ca waves. The mechanisms by which large numbers of myocytes synchronously 
develop Ca waves sufficient to induce a DAD in tissue is still under investigation [23, 24]. 
In one-dimensional (1D) tissue, however, the number of myocytes required falls 
dramatically, into double digits [22]. This may be one reason why Purkinje fibers, which are 
quasi-1D cables, are more susceptible to DADs than 3D ventricular tissue, although 
electrophysiological differences such as a lower density of inward rectifier K channels also 
contributes. Other factors affecting source-sink relationships in tissue can also markedly 
reduce the number of myocytes required for a DAD-mediated PVC to emerge. For example, 
fibrosis has the effect of electrically insulating strands of myocytes from one another, 
effectively converting 3D tissue into a network of interconnected 1D cables [25, 26]. When 
DADs do overcome the source-sink mismatch in tissue, PVCs and focal ventricular 
tachycardia (VT) can result. Bidirectional VT, a hallmark of CPVT [17] and Ca-overload 
induced by digitalis toxicity [27, 28], has been explained by reciprocating bigeminy in 
which DAD-triggered APs arising from different regions of the His-Purkinje system trigger 
each other in a ping-pong fashion [29].
In addition to PVCs triggered by DADs, unstable Ca cycling can simultaneously 
dynamically increase substrate vulnerability by two mechanisms: promoting dispersion of 
excitability, and promoting dispersion of refractoriness. In the first case, regions of tissue in 
which DADs do not reach the threshold to trigger an AP can nevertheless depolarize the 
resting membrane voltage sufficiently to depress excitability by inactivating Na channels. 
This can lead to regional conduction block of impulses arising from adjacent regions with 
supra-threshold DADs, thereby initiating reentry [30, 31]. In the second case, the rapid rates 
during DAD-induced triggered activity can also promote Ca transient alternans (manifesting 
clinically as pulsus alternans in heart failure) which secondarily causes APD to alternate, 
equivalent to T wave or repolarization alternans (for review see [32]). APD alternans, when 
coupled to conduction velocity (CV) restitution, results in spatially discordant APD 
alternans [33, 34]. During spatially discordant APD alternans, APD alternates in a long-short 
pattern in some regions but a short-long pattern in adjacent regions, producing a steep APD 
gradient between the two regions (Fig. 2A). This makes the tissue highly vulnerable to 
initiation of reentry [35], since a DAD-mediated PVC arising from the region with short 
APD encounters a gradient of increasing refractoriness as it propagates into the region with 
long APD. If this APD gradient is too steep, the impulse will block and propagate around 
the long APD region until it regains excitability, and then reenter this region retrogradely to 
induce reentry, as illustrated in Fig. 2A (beat #2). Once reentry is induced, the arrhythmia 
can either self-terminate by colliding with a border, or degenerate into multiple wavelet or 
mother rotor VF.
Spatially discordant APD alternans is also a mechanism by which extremely rapid pacing 
(>300 beats per min) induces VF in completely normal hearts [32, 35]. Normally, such fast 
heart rates are not physiologically achievable, so that VF arising directly from sinus 
tachycardia in normal hearts is extremely uncommon. However, VF is almost universally 
inducible by very rapid external pacing in normal hearts. In heart failure and acute ischemia, 
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the threshold required to induce spatially discordant alternans decreases to much slower 
heart rates, as evidenced clinically by pulsus alternans and frank or microvolt T wave 
alternans, both of which portend an increased risk of sudden cardiac death [32, 36–38]
Dynamic factors/targets—The relationship between SR Ca release and SR Ca load (Fig. 
2A) plays a key role in the genesis of both Ca waves causing DADs and Ca alternans 
leading to spatially discordant APD alternans (for review see [39]). The SR Ca release-load 
relationship in cardiac myocytes is normally very steep [40, 41], such that as the SR Ca load 
increases, the probability that spontaneous openings of RyRs in one region of a myocyte will 
trigger a regenerative Ca-induced Ca release wave that propagates throughout the myocyte 
to cause a DAD also increases. A steep SR Ca release-load relationship also promotes Ca 
alternans [42]. Dynamically, the SR Ca release-load relationship can be thought of as an 
input-output relationship with a high gain. If a large amount of SR Ca is released on one 
beat, the SR is depleted to a greater extent and may not be able to refill to the same level 
before the next beat arrives. The lower SR Ca then results in a smaller release, causing less 
SR depletion, which allows the SR to refill to a higher level before the next beat, causing a 
large release, and so forth, generating an alternating large-small-large-small release pattern. 
This mechanism of Ca alternans is called SR load-dependent Ca alternans. In addition, Ca 
alternans can result from an SR load-independent mechanism due to RyR refractoriness 
[43]. The consequence of Ca alternans is APD alternans, since the Ca transient amplitude 
affects Ca-sensitive currents regulating APD, including the L-type Ca current (ICa,L), the 
slow component of the delayed rectifier K current (IKs) and INCX. This relationship is 
referred to as Ca-voltage coupling [44], and can be either positive (a large Ca transient 
prolongs APD) or negative (a large Ca transient shortens APD), depending on whether the 
net effect on Ca-sensitive currents is inward or outward. Finally, Ca alternans in cardiac 
myocytes can become spatially discordant at the subcellular levels, such that one region of 
the myocyte exhibits a large-small pattern of Ca release, whereas another region exhibits a 
small-large pattern [45, 46]. This tends to attenuate APD alternans, since the whole cell Ca 
transient shows less beat-to-beat variation when regions are alternating out-of-phase with 
each other.
In addition to Ca alternans, APD alternans can be caused by steep APD restitution [32, 47]. 
APD restitution refers to the dependence of APD on the previous diastolic interval (DI). 
Normally, when heart rate increases, APD also shortens in order to preserve diastolic filling 
time and coronary blood flow. This relationship, plotted graphically in Fig. 2A, also 
represents an input-output relationship. At a constant heart rate, the cycle length equals the 
sum of the APD and DI, so that if the DI is short, then the subsequent APD will be short. 
That will prolong the DI before the next beat arrives, causing a long APD. This long APD 
means a shorter DI, so the next beat will have a shorter APD, and so forth, in an alternating 
long-short-long-short pattern. Dynamical analysis reveals that the slope of the APD 
restitution curve is a critical determinant of whether the APD alternans will gradually 
disappear (slope <1) or increase (slope >1) to cause persistent APD alternans (or block). In 
reality, the situation is somewhat more complex, because although the previous DI has a 
powerful influence of the subsequent APD, it is not the sole determinant. The other 
determinants are collectively referred to as memory effects, so that the onset of APD 
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alternans often does not correlate precisely with APD restitution slope >1 [48]. 
Nevertheless, other factors being equal, flattening APD restitution slope will suppress APD 
alternans and vice versa.
A third dynamic factor that plays a critical role in whether APD alternans becomes spatially 
discordant is CV restitution [33, 34, 49]. CV restitution is the dependence of CV on the 
previous DI (Fig. 2A). At very short DI, incomplete recovery from inactivation of INa causes 
CV to slow. Dynamically, this acts once again as an input-output relationship for a wave 
propagating through tissue. At very short DI, the wavefront slows, increasing its DI with 
respect to the wave in front of it. As the DI becomes longer, however, the APD prolongs, 
which shortens the DI of the wave behind it, initiating a chain reaction that causes the APD 
(and CV) to oscillate as the wave moves through the tissue, resulting in spatially discordant 
APD alternans. In this situation, APD alternans drives oscillations in the waveback, whereas 
CV restitution drives oscillations in the wavefront, together creating head-tail interactions 
that, if unstable and self-amplifying, can lead to wavebreak. In promoting spatial 
discordance, the steepness of CV restitution is not as important as the range of DI over 
which the CV varies. Therefore we refer to “broad,” rather than “steep,” CV restitution as 
promoting spatially discordant alternans. Premature beats arising from a different location in 
the tissue can convert spatially concordant APD alternans to spatially discordant alternans 
[34]. Fixed factors, such as pre-existing APD gradients or tissue fibrosis, can markedly 
reduce the threshold of dynamic instability required for spatially discordant alternans to 
develop [50].
There are also mechanisms that generate APD alternans at normal or slow heart rates in the 
settings of reduced or excessive repolarization reserve [51], but these do not typically 
generate spatially discordant alternans because the rate is too slow to engage CV restitution. 
Other dynamic mechanisms promote electrical dispersion in these settings, as discussed 
later.
Molecular factors/biological targets—The strategy to identify molecular factors as 
biological targets to suppress DADs and spatially discordant APD alternans requires a 
multiscale analysis. First, how molecular factors relate to the dynamic factors and fixed 
factors promoting Ca waves and Ca alternans at the subcellular level must be defined. Next, 
how these subcellular behaviors relate to DADs and APD alternans at the cellular level must 
be defined. Finally, how these cellular behaviors relate to DAD-mediated PVCs and 
spatially discordant APD alternans at the tissue level must be defined. In addition, to qualify 
as biological targets, molecular factors must meet two equally important criteria – that they 
do not impair normal excitation-contraction (EC) coupling, and do not exacerbate the 
dynamic factors promoting arrhythmias in the other two major arrhythmia dynamics 
categories.
At the subcellular level, the task is to identify molecular factors regulating the dynamic 
factors promoting Ca waves and Ca alternans. The theoretical analysis of Ca cycling has 
revealed three key dynamic factors underlying the emergence of Ca waves and Ca alternans: 
random activation, refractoriness and recruitment of Ca release units in their subcellular 
network (the 3 R’s theory) [39, 52]. The regulation of the 3 R’s by molecular factors, 
Weiss et al. Page 9
J Mol Cell Cardiol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
however, is very complex, since Ca cycling proteins not only affect the 3 R’s directly, but 
also indirectly by altering SR Ca load. Nevertheless, the theory provides a comprehensive 
computational framework to systematically identify properties of Ca cycling proteins that 
can be targeted to suppress Ca waves and Ca alternans, for example by altering RyR 
properties or upregulating SERCA activity, without adversely impacting normal Ca cycling 
and excitation-contraction coupling.
At the cellular level, an important dynamic factor for DAD formation is the sensitivity of 
diastolic membrane voltage to spontaneous SR Ca release, referred to as the diastolic Ca-
voltage coupling gain [53]. For example, when a Ca wave stimulates INCX to generate a 
DAD in a myocyte, the amplitude of the DAD depends on the resting K conductance, 
mainly determined by the inward rectifier K current IK1, relative to the amplitude of INCX. 
When resting K conductance is low, the same INCX will generate a much larger DAD than 
when resting K conductance is high, facilitating DAD-mediated triggered activity. In heart 
failure, IK1 is down-regulated by approximately 50% while INCX is typically doubled [54], 
important factors contributing to the increased incidence of DAD-mediated triggered 
activity in failing hearts. Therefore, IK1 is an important molecular factor that directly 
regulates a dynamic factor (diastolic Ca-voltage coupling gain) that controls DAD 
amplitude. This could be a potential biological target, with the caveat that its effects on 
normal EC coupling and other dynamic factors in all three arrhythmia categories must be 
shown to be neutral or anti-arrhythmic.
Another key dynamic factor at the cellular level is APD restitution slope, which, if steep 
(>1), promotes APD alternans and spiral wave breakup initiating multiple wavelet VF [55]. 
A multitude of molecular factors affect APD restitution slope, but one of the most influential 
determinants is ICa,L, specifically its kinetics of recovery from inactivation. By reducing the 
influence of ICa,L on APD, Ca channel blockade flattens APD restitution slope, thereby 
suppressing voltage-driven APD alternans [56], and also inhibits DADs by reducing cellular 
Ca loading. However, the degree of Ca channel blockade required to produce these effects 
also significantly depresses EC coupling, making Ca channel blockade impractical as an 
antiarrhythmic strategy. Moreover, although Ca channel blockade suppresses voltage-driven 
APD alternans, it can promote Ca-driven APD alternans [52, 57], which is pro-arrhythmic. 
These adverse effects of Ca channel blockade arise largely from suppressing the early peak 
of ICa,L which is critical for normal EC coupling. However, modifying the kinetics of 
inactivation and recovery from inactivation of ICa,L alone, without suppressing the early 
peak current can flatten APD restitution slope without greatly impacting the whole cell Ca 
transient amplitude [58]. Thus, modification of ICa,L kinetics could be a potential molecular 
factor to target, assuming it does not adversely affect dynamic factors in the other 
arrhythmia categories.
At the tissue level, an important dynamic factor promoting spatially discordant APD 
alternans is broad CV restitution [33, 34]. The main molecular factor controlling CV 
restitution is recovery of inactivation of INa. Speeding INa recovery from inactivation 
reduces the range of DI over which CV varies, and is a potential molecular factor that could 
serve as a biological target. Conversely, slowing INa recovery from inactivation broadens 
CV restitution, which promotes spatially discordant APD alternans. Na channel blockers 
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typically slow INa recovery from inactivation [59], and the increased propensity to develop 
spatially discordant APD alternans may have contributed to the excess mortality in patients 
treated with Na channel blockers in the CAST study [7], despite the >80% reduction in 
PVCs. Chronic and acute ischemia also slow INa recovery from inactivation [59–61], 
potentiating spatially discordant APD alternans.
Fixed factors causing electrical dispersion can also be biological targets. Fibrosis plays a key 
role in both promoting triggers and creating a vulnerable tissue substrate [26]. The source-
sink relationship is much more favorable for DADs (and EADs) to emerge and cause 
triggered activity in moderately fibrotic tissue than in normal tissue [22]. Fibrosis also 
promotes spatially discordant APD alternans [50] and slow conduction, facilitating reentry. 
Molecular interventions that reverse fibrosis completely could have powerful antiarrhythmic 
actions. A caveat, however, is that if such agents only partially reverse fibrosis, such that 
regions of severe fibrosis were converted to moderate fibrosis, the net effect could be 
proarrhythmic. This is because impulses that cannot propagate into or out of severely 
fibrotic tissue may regain the ability to propagate slowly through moderately fibrotic 
regions, unmasking sources for triggers and creating new slow conduction pathways for 
reentry.
The above are only a few conceptual examples illustrating how molecular factors can be 
related to subcellular, cellular and organ scale dynamic and fixed factors promoting DADs 
and spatially discordant APD alternans. Their plausibility as biological targets, however, 
depends on systematically demonstrating that they do not interfere with normal EC coupling 
and do not exacerbate the dynamic factors controlling the other arrhythmia categories.
3.2. Arrhythmias Related to Reduced Repolarization
Clinical settings—The prototype clinical settings for this dynamical category of 
arrhythmias are the congenital and acquired LQT syndromes, in which repolarization 
reserve is reduced due to either decreased outward or increased inward currents during the 
AP plateau [62, 63]. Heart failure is also associated with reduced repolarization reserve as a 
result of electrical remodeling [19, 64], predisposing the failing heart to this category of 
arrhythmias in addition to arrhythmias in the unstable Ca cycling category discussed above 
in section 3.1.
Arrhythmia mechanisms—In this category, EAD-mediated PVCs and triggered activity 
are the major triggers which can initiate TdP, polymorphic VT, and/or mixed focal-reentrant 
VF.
Dynamical mechanisms—When repolarization reserve is reduced, myocytes become 
susceptible to EADs [65, 66]. At the cellular level, EADs often exhibit chaotic and bistable 
behaviors [15, 67]. At the tissue level, these factors lead to EAD-mediated arrhythmias 
arising from regional chaos synchronization and biexcitability. The relevant subcellular, 
cellular and tissue level mechanisms are discussed below.
At the subcellular level, spontaneous SR Ca release due to a mix of Ca waves and ICa,L-
triggered Ca release before repolarization is complete can stimulate inward INCX, thereby 
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slowing and/or transiently reversing repolarization [68–70]. However, as voltage depolarizes 
and/or the Ca elevation subsides, inward INCX decreases and cannot by itself trigger an AP 
at the cellular level. A regenerative current is required for the latter. This most commonly 
involves reactivation of ICa,L, although if the takeoff potential of the EAD is sufficiently 
low, as in a phase-3 EAD, INa reactivation can also be involved [71].
At the cellular level, the major factor promoting EADs of sufficient amplitude to trigger an 
AP is ICa,L [72]. The dynamics of the process is now reasonably well-understood (for review 
see [66]). APD prolongation by itself is not sufficient to induce EADs, since if the 
membrane voltage remains above 0 mV, there is no possibility of reactivating ICa,L. When 
the membrane voltage falls below 0 mV, however, the window region of ICa,L is engaged, 
such that L-type Ca channels are neither fully activated nor fully inactivated (Fig. 3B). 
Depending on the relative rates at which L-type Ca channels recover from inactivation and 
K channels deactivate as the AP repolarizes into this voltage window, the membrane voltage 
may begin to oscillate as a result of a Hopf bifurcation [73]. A Hopf bifurcation is a generic 
cause of oscillations in systems containing positive and negative feedback loops which are 
coupled with a time delay (other examples include the cell cycle and sinus node 
pacemaking). In the case of EADs, the positive feedback element is the reactivation of ICa,L, 
such that as voltage increases during the EAD upstroke, ICa,L is further activated, causing 
more rapid depolarization, and so forth. The negative feedback elements are the inactivation 
of ICa,L and the activation of IKs (or other outward currents) as the membrane depolarizes 
during the EAD upstroke, which causes the cell to repolarize. The time constants of 
inactivation/recovery from inactivation of ICa,L and activation/deactivation of IKs must be in 
a properly balanced range for oscillations to develop. A characteristic feature of Hopf 
bifurcation dynamics is that the oscillations grow in amplitude over time, eventually 
repolarizing the voltage to a negative enough level to allow full blown reactivation of ICa,L 
to elicit triggered activity. Eventually, the oscillations amplify to a level that engages 
another type of bifurcation, called a homoclinic bifurcation, which terminates the 
oscillations and triggered activity, leading to full repolarization [73]. This Hopf-homoclinic 
bifurcation scenario is similar to that underlying bursting behavior in neurons[74, 75]. In the 
case of EADs, the Hopf-homoclinic bifurcation dynamics do not result solely from the ICa,L-
IKs interaction independently of other ionic currents. Rather, all of the ionic currents 
influencing repolarization must be balanced in a certain range for the EAD dynamics to 
emerge. The key requirement is for the rate of repolarization to be delayed as the plateau 
voltage falls below 0 mV. This is the reason why triangular-shaped APs are more 
susceptible to EADs than long square-shaped APs in which voltage remains above 0 mV 
[76]. It also explains why Ito, despite being an outward K current, can promote EADs by 
holding the early plateau voltage at a lower level, which delays the activation of IKs and 
thereby reduces repolarization reserve during the late phase of the plateau [77]. Fibroblast 
coupling to myocytes can have a similar effect [78]. Thus, repolarization reserve evolves 
dynamically during the AP plateau phase, and is impacted by all ionic currents during the 
plateau, even though the active dynamics underlying the oscillations are primarily mediated 
by the ICa,L-IKs interaction. An analogy can be drawn to pacemaking by ventricular 
myocytes – IK1 normally stabilizes the resting voltage of myocytes, preventing automaticity 
from emerging. If IK1 is suppressed, however, the myocyte develops spontaneous diastolic 
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depolarization by allowing other conductances, such as If, to depolarize the resting potential 
to the activation threshold. Similar to IK1, most of the ionic conductances during the AP are 
passively summating to determine whether or not the background is permissive for the 
active currents to generate the voltage oscillations. Therefore, repolarization reserve is not a 
static factor that is either high or low, but a key dynamic factor linking alterations of many 
different outward and inward ionic currents to EAD susceptibility. This accounts for the 
wide variety of genetic causes of LQT syndromes (currently LQT1-LQT13) as well as drugs 
inducing acquired LQT syndrome. Various signaling pathways (adrenergic, Ca-calmodulin 
kinase) and electrolyte disturbances (hypokalemia, hypomagnesemia) can also modify 
channel properties to make myocytes more vulnerable to EADs.
Whereas the Hopf bifurcation initiates the voltage oscillations during the EAD, a homoclinic 
bifurcation terminates the oscillations and causes repolarization [73]. The homoclinic 
bifurcation mechanism is important because its dynamical signature is chaos. That is, the 
termination of voltage oscillations during the EAD is a chaotic process, such that at a 
constant heart rate, the pattern of EADs will vary unpredictably, with some beats exhibiting 
one or many EADs, while other beats repolarize without EADs. The chaotic behavior of 
EAD termination has important consequences at the tissue level, referred to as regional 
chaos synchronization [15]. The principle is straightforward. When two myocytes are 
coupled electrotonically via gap junctions, they cannot exhibit markedly different AP 
waveforms, since any voltage difference between the cells causes electrotonic current to 
flow through gap junctions (by Ohm’s law), which hyperpolarizes the more depolarized cell, 
and conversely depolarizes the more hyperpolarized cell. Thus, if one myocyte is set to have 
an EAD but its neighbor is not, one or the other will predominate, and either both myocytes 
will have an EAD or both will repolarize. When this situation is extended to cardiac tissue 
level, in which thousands of myocytes are electrotonically coupled to each other, democracy 
rules. In regions in which a large majority of myocytes are poised to have an EAD (EAD+ 
myocytes), they will force all of the myocytes in that region will exhibit an EAD. However, 
in regions in which less than the critical majority are poised to have an EAD (EAD− 
myocytes), all of the cells will repolarize. The chaotic behavior of EADs therefore can tip 
the balance in either direction, so that some regions fall below the critical threshold of EAD
+ myocytes, while other regions are above the threshold. The result is the formation of 
islands of myocytes all exhibiting EADs, between which are interposed regions without 
EADs (Fig. 2B). The size of the EAD islands (referred to in dynamics as their characteristic 
length scale) depends on the violence of the chaos (tending to create voltage differences) 
relative to the strength of electronic coupling (tending to smooth voltage differences) [15, 
66]. On each beat, the pattern changes unpredictably (compare beat #1 and beat #2, Fig. 2B). 
The result is marked dispersion of refractoriness whose pattern changes on each beat. 
Moreover, if one of the EAD islands reaches the threshold to trigger an AP which 
propagates unidirectionally (due to the irregular contour of the EAD island) into adjacent 
repolarized tissue, the impulse can potentially reenter the EAD region after it repolarizes and 
thereby induce reentry (illustrated in beat #1, Fig. 2B). Alternatively, the triggered AP can 
propagate out of the EAD island until it encounters an adjacent EAD island which has not 
yet repolarized. If the APD gradient is steep enough, wavebreak can result, initiating reentry 
(illustrated in beat #2 in Fig. 2B). The resulting arrhythmia involves a mixture of EAD-
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mediated triggered activity and reentry, manifesting as polymorphic VT which can quickly 
degenerate into mixed focal-reentrant VF.
Reentry induced by EAD-mediated arrhythmias also can exhibit an unusual property. It has 
been known for decades that under some conditions of reduced repolarization reserve (such 
as hypokalemia), myocytes can exhibit two stable resting membrane potentials, one near 
−80 mV and the second at a more depolarized voltage around −50 mV [79], a phenomenon 
known in dynamics as bistability. When the combination of EAD-mediated triggers and 
electrical dispersion created by EAD islands leads to initiation of reentry, the resulting rotors 
can arise from either resting potential [67, 80]. If the rotor arises from the more polarized 
resting potential, the rotor propagates primarily via INa (with ICa,L activated secondarily). 
However, if the rotor arises from the depolarized resting potential, at which INa is 
inactivated, ICa,L mediates propagation. We call this condition biexcitability, such that either 
INa- or ICa,L-mediated rotors, or mixtures of the two, can coexist in the same tissue. Whereas 
INa-mediated rotors have a very rapid rate, typically around 600 beats per min, ICa,L-
mediated rotors are much slower, in the range of 150–300 beats per min. ICa,L-mediated 
rotors also tend to meander, causing the QRS morphology to vary. These features of ICa,L-
mediated rotors match both the typical rates and varying QRS morphologies of TdP, in 
contrast to INa-mediated rotors which are much faster and produce the high frequency 
activation more characteristic of VF. We have proposed that as ischemia develops during 
TdP or polymorphic VT, the activation of ATP-sensitive K channels increases repolarization 
reserve and converts ICa,L-mediated rotors to INa-mediated rotors, causing degeneration of 
TdP and polymorphic VT into multiple wavelet or mother rotor VF [81].
It is important to note that the EAD-mediated arrhythmias described above can all originate 
purely from dynamic mechanisms, in the absence of any fixed factors, such as pre-existing 
structural or electrophysiological tissue heterogeneities [66]. This can be demonstrated in 
computer simulations performed in completely homogeneous isotropic cardiac tissue. Fixed 
factors creating electrical dispersion, however, generally lower the threshold of dynamic 
instability required to generate these behaviors. Thus, real cardiac tissue, which always 
contains pre-existing heterogeneities, is inherently more sensitive to the emergence of these 
dynamic instabilities, and becomes even more sensitive when disease processes exacerbate 
the degree of heterogeneity further as a result of electrical and structural remodeling. For 
example, phase 3 EADs caused by tissue heterogeneities have been shown to initiate 
reentrant arrhythmias [82].
Dynamic factors/targets—At the subcellular level, Ca cycling abnormalities that 
promote spontaneous SR Ca release and Ca waves during diastole can also generate 
spontaneous Ca release during systole, contributing to the formation of EADs by stimulating 
inward INCX. This may be an important factor in phase-3 EADs, since inward INCX 
amplitude is enhanced at negative voltages. Thus, dynamical targets designed to suppress 
spontaneous Ca release and DADs based on the 3R theory described in section 3.1 [39, 52] 
may potentially have efficacy against EAD-mediated arrhythmias.
At the cellular level, the main dynamic factor regulating EAD behaviors can be observed 
from the APD restitution curve (Fig. 2B), which exhibits a very steep region corresponding 
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to the sudden APD prolongation when EADs appear (Fig. 2B) due to the Hopf-homoclinic 
bifurcation mechanism. As noted earlier, from a dynamics standpoint APD restitution is an 
input-output relationship, since the preceding DI determines the APD for the next beat, but 
the APD of the next beat determines the next DI, and so forth. The slope is the gain of this 
input-output function, so that steeply-sloped regions act as amplifiers of small differences, 
creating instability. In LQT syndromes, one manifestation of this instability is APD (and T 
wave) alternans [83], which can occur when heart rate is such that the DI falls in the steeply-
sloped region of the APD restitution curve [51]. These DIs may correspond to slow or 
normal heart rates in LQT syndromes. Since CV restitution (which occurs at very short DI) 
is not typically engaged, APD alternans is not likely to become spatially discordant at the 
tissue level. Instead, electrical dispersion at the tissue level is generated when the EAD 
behavior becomes chaotic and the chaos synchronization mechanism comes into play, as 
described above [15, 66]. The chaotic EAD behavior is also predicted from the APD 
restitution curve, since not only does the region of the Hopf-homoclinic bifurcation have a 
very steep slope, but a portion of this region is negatively-sloped (Fig. 2B). The latter is a 
well-recognized generator of higher order periodicities and chaotic behavior, as can be 
readily demonstrated by a cobweb diagram [15]. Eliminating this steeply-sloped region in 
the APD restitution curve is predicted not only to prevent EADs and EAD chaos at the 
cellular level, but also to prevent EAD chaos synchronization at the tissue level. This is a 
powerful dynamic factor to target, since it simultaneously prevents EADs from generating 
PVCs as triggers and from creating marked dispersion of refractoriness by forming EAD 
islands.
Molecular factors/biological targets—Molecular factors, if appropriately identified, 
can be targeted to suppress subcellular, cellular, or tissue scale dynamic factors promoting 
the instability creating EADs. At the subcellular scale, Ca waves play a facilitatory role in 
EAD generation. Thus, molecular factors targeting the 3R’s as dynamic factors at the 
subcellular scale may potentially have favorable effects at suppressing EAD- and as well as 
DAD-mediated arrhythmias.
At the cellular scale, a promising dynamic target for EADs is the steep APD restitution 
curve, reflecting the underlying Hopf-homoclinic bifurcation sequence that generates 
chaotic behavior of EADs. This is a potent target since it generates not only EADs at the 
cellular scale, but is also allows chaos synchronization to generate both triggers and a 
vulnerable substrate at the tissue scale. What molecular factors control the Hopf-homoclinic 
bifurcations? There are many potential candidates, since, as noted above, all ionic currents 
during the AP plateau are involved in setting the conditions for the Hopf-homoclinic 
bifurcation to occur and generate chaotic EADs. Most of these currents play relatively 
passive background roles at reducing overall repolarization reserve, whereas the key active 
currents generating the oscillatory dynamics are ICa,L and IKs, and in some cases, INa [84]. 
Two examples, one from the passive group (late INa) and one from the active group (ICa,L), 
are discussed below.
Late INa—One of the common congenital LQT syndromes, LQT3, is caused by mutations 
that interfere with inactivation of INa, such that a small component of residual inward 
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current, called late INa (typically only 1–2% of the peak current, remains active during the 
AP plateau [85]. This increase in inward current relative to the normal outward K currents 
during the AP plateau reduces repolarization reserve, setting the stage for EADs to occur. 
The importance of late INa, however, is not restricted to LQT3. Late INa is also induced by 
signaling pathways which modify Na channel function, notably CaMKII activation [86] and 
phosphoinositol 3 kinase (PI3K) inhibition [87]. CaMKII signaling is activated in heart 
failure by both Ca overload and oxidative stress [18]. Moreover, late INa poses an increased 
Na load on the heart, which contributes to the rise in intracellular [Na] during heart failure, 
secondarily potentiating Ca overload by inhibiting forward INCX [88]. The Ca overload 
causes further activation of CaMKII, initiating a positive feedback cycle. PI3K signaling has 
recently been shown to be inhibited by a variety of IKr blocking drugs known to cause 
acquired LQT syndrome, such as dofetilide [87]. These observations have stimulated 
considerable interest in drugs that selectively block late INa, without depressing the early 
peak INa, such as the antianginal agent ranolazine and newer derivatives. Unlike other Na 
channel blockers which block both peak and late INa, ranolazine does not appear to increase 
mortality in patients with coronary artery disease or heart failure [89], and in experimental 
studies has been shown to potently suppress EAD-mediated arrhythmias [90, 91]. The 
reason may be that drugs selectively blocking late INa do not simultaneously exacerbate 
arrhythmia risk by potentiating spatially discordant APD alternans (via broadening CV 
restitution) and conduction block like drugs blocking peak INa.
ICa,L—ICa,L is a molecular factor that plays a key dynamic role in EAD generation. ICa,L 
normally has a substantial late component, averaging 10–20% of peak ICa,L. Genetic 
mutations that interfere with voltage- or Ca-induced inactivation of ICa,L and thereby 
increase this late component of inward current during the AP plateau cause clinical LQT 
syndromes [92]. CaMKII activation and drugs such as BayK4688 which reduce 
repolarization reserve by increasing both peak and late ICa,L also are potent generators of 
EADs and EAD-mediated arrhythmias [18]. The major factor promoting the EAD upstroke 
is reactivation of ICa,L, which is determined by the properties of ICa,L in the window current 
range from approximately −40 to 0 mV [72]. In this voltage range, ICa,L is neither fully 
activated nor inactivated, and generates a sustained current that regeneratively increases 
from −40 to −20 mV, after which it peaks and then falls off to the late ICa,L pedestal 
component above 0 mV. Fig. 3B illustrates the quasi-steady state ICa,L window conductance, 
measured 300 ms after a voltage clamp to different membrane potentials. As the voltage 
during the AP plateau repolarizes into this voltage range, the ICa,L window current grows 
larger as channels recover from inactivation. The rate at which the current increases is 
governed by the time constant of recovery from inactivation. Since the rate of repolarization 
is normally too rapid for much recovery to occur, ICa,L remains too small to reverse 
repolarization. If the rate of repolarization has been slowed, because of reduced outward K 
currents like IKr or IKs or increased inward currents like late INa or late ICa,L, then the 
recovery of ICa,L may be adequate to reverse repolarization and initiate an EAD. The 
amplitude of the EAD depends on how much ICa,L is available to be reactivated, such that 
the lower the take-off potential of the EAD, the larger its amplitude. In this scenario, both 
the size and the kinetics of the ICa,L window region play major roles. EADs can be 
powerfully suppressed by manipulating the size of the ICa,L window current region in a 
Weiss et al. Page 16
J Mol Cell Cardiol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
manner that does not suppress the peak ICa,L critical for regulating Ca release and normal 
EC coupling. Fig. 3 illustrates the effects of a modest 5 mV depolarizing shift in the voltage 
dependence of the steady state activation to reduce the overlap between these curves and 
make the window current region smaller. This intervention had no major effect on the peak 
ICa,L, Ca transient amplitude or APD, but potently suppressed EADs induced by either 
oxidative stress (H2O2) or modest hypokalemia [93]. Hyperpolarizing the steady state 
inactivation curve by 5 mV to reduce the window current region had comparable effects, as 
did reducing the late ICa,L non-activating pedestal current. In contrast, altering other ICa,L 
parameters, such as time constants of activation, inactivation and recovery from inactivation 
or the slopes of steady state activation and inactivation curves had less reliable effects 
(Olcese R, unpublished observations). These studies demonstrate that it is possible, in 
principle, to modify the biophysical properties of ICa,L to suppress EADs, while preserving 
peak ICa,L and normal EC coupling. This raises the possibility that a drug that selectively 
blocks late ICa,L, analogous to the manner in which ranolazine selectively blocks late INa, 
could have powerful antiarrhythmic effects at suppressing EAD-mediated arrhythmias, 
either alone or in combination with a drug that blocks late INa. Identifying compounds that 
selectively block late ICa,L seems plausible, given the overall structural similarities between 
gating of Na and Ca channels and the fact that selective late INa blockers such as ranolazine 
already exist and are in clinical use. The biophysical properties of ICa,L could potentially 
also be modified by altering the subunit composition of L-type Ca channels. Cardiac L-type 
Ca channel complexes are comprised of pore-forming α subunit as well as accessory α –δ 
and β subunits. The β subunits have a large number of isoforms expressed differentially in 
various tissues. In heart, the predominant isoform is the β2a subunit, which confers a 
relatively large non-inactivating pedestal component to ICa,L, but other β subunits have 
different effects on inactivation which may potentially reduce the size of the ICa,L window 
current region [94]. This raises the possibility of a gene therapy approach to replace the 
native β subunits with β3.
At the tissue level, the dynamical factors that regulate the spatial scale at which EAD islands 
form during regional chaos synchronization also can be potentially targeted by molecular 
factors. As noted above, the characteristic length scale at which these islands form is 
determined by the violence of the chaos generating EADs relative to the smoothing effect of 
electrotonic coupling [15]. The latter is determined by gap junction coupling between 
adjacent myocytes. If gap junction coupling is very strong, the characteristic size of the 
EAD islands increases, and if the characteristic size exceeds the physical size of the 
ventricles, then multiple islands cannot form, reducing both the dispersion of refractoriness 
and frequency of EAD-triggered activity in the tissue. Thus, drugs that increase gap junction 
conductance could have antiarrhythmic properties. Similarly, molecular interventions that 
prevent gap junction remodeling or fibrosis (which effectively reduces myocyte-myocyte 
coupling by interposing fibrous strands between myocytes) in diseased hearts could have 
beneficial effects by this mechanism.
We have used the above examples to illustrate how molecular factors might be targeted to 
suppress the dynamical factors causing EAD-mediated arrhythmias, but these represent only 
a few of myriad possibilities. Many other potential interventions targeting various 
biophysical properties of different ion channels/transporters, their trafficking and regulation 
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by various signaling pathways are also possible, once the proper framework for 
systematically evaluating their dynamical effects has been established. As with DAD-
mediated arrhythmias, fixed factors can also be biological targets for EAD-mediated 
arrhythmias. Fibrosis again plays a key role in both promoting triggers and creating a 
vulnerable tissue substrate [26]. The source-sink relationship is much more favorable for 
EADs to emerge and cause triggered activity in moderately fibrotic tissue than in normal 
tissue [22, 95]. Fibrosis also promotes slow conduction and conduction block, facilitating 
initiation of reentry by EAD-mediated PVCs.
Even if pharmacologic or gene therapy-based approaches to prevent EAD-mediated 
arrhythmias can be identified, they must not interfere with normal EC coupling if they are to 
be clinically useful. For example, in animal models currently available Ca channel blockers 
which block both peak and late ICa,L are very effective at preventing EAD-mediated 
arrhythmias as well as arrhythmias related to Ca cycling instabilities. However, the doses 
required markedly impair EC coupling, which limits their usefulness clinically. Second, the 
intervention must not increase susceptibility to ventricular arrhythmias in the other dynamic 
categories. These issues have yet to be fully evaluated for the molecular factors, such as late 
INa blockers or the ICa,L- modifying interventions, discussed above.
3.3. Arrhythmias Related to Excess Repolarization
Clinical settings—The prototype clinical settings for this dynamical category of 
arrhythmias are Brugada Syndrome, Early Repolarization Syndrome, and Short QT 
Syndromes [96, 97]. In these cases, excessive repolarization reserve is classically caused by 
decreased inward current (Na or Ca channel loss-of-function mutations) or increased 
outward current (K current gain-of-function mutations) affecting the AP plateau. Acute 
myocardial ischemia is also associated with excessive repolarization reserve as a result of 
activation of the ATP-sensitive K current (IKATP) and decreased INa and ICa,L, which, 
together with accompanying Ca cycling instabilities, to promote arrhythmias.
Arrhythmia mechanisms—Excessive repolarization reserve causes all-or-none 
repolarization which can promote phase 2 reentry [98], resulting in reentrant VT and/or 
multiple wavelet or mother rotor VF. Phase-3 EADs arising from a short APD can also 
occur in the settings of SQT syndromes and acute ischemia.
Dynamical mechanisms—At the cellular level, the main dynamic factor regulating 
arrhythmias in this category manifests itself in the APD restitution curve (Fig. 2C) [99], 
which exhibits a very steep region corresponding to the all-or-none early repolarization of 
the AP. All-or-none repolarization is a feature arising primarily in epicardial ventricular 
myocytes with a prominent early notch in the AP before the plateau fully develops, called a 
spike-and-dome morphology, as seen in the traces in Fig. 2C. The early repolarization phase 
(phase 1) is caused by Ito, which is largest in the right ventricle epicardium. In Fig. 2C, APD 
is relatively normal at short DI because Ito is small, having not yet recovered from 
inactivation. As the DI becomes longer, Ito has more time to recover and progressively 
increases. If Ito has a large enough density and increases sufficiently, inward Na and Ca 
currents are no longer able to sustain the AP plateau, and the AP suddenly repolarizes, 
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causing all-or-none repolarization. Note that just before reaching the DI at which APD 
suddenly shortens, APD prolongs due to an accentuation of the AP dome. The upstroke of 
the accentuated AP dome in the setting of excessive repolarization reserve plays the same 
role as the upstroke of an EAD in the setting of reduced repolarization reserve. If the 
upstroke is rapid enough, the AP dome can propagate into adjacent regions of tissue with 
shorter APD that have already repolarized and recovered excitability. When Ito density is 
heterogeneous in different regions of the epicardium, a stimulated beat which propagates 
into a region with high Ito density can develop early repolarization and very short APD, 
whereas an adjacent regions with slightly less Ito density can develop an AP with a large 
dome that then propagates unidirectionally into the very short APD region, generating a 
closely-coupled PVC. The PVC can then propagate through the short APD region until the 
region with the AP dome repolarizes, and then reenter this region to induce phase 2 reentry 
(Fig. 2C). Alternatively, the PVC may encounter an adjacent region with longer APD, 
causing wavebreak and initiation of reentry (Fig 2C).
Heterogeneous Ito distribution, however, may not be required for phase 2 reentry. In the 
simulation shown in Fig. 2C, the tissue is completely homogeneous. This highlights the 
second consequence of the steeply-sloped region of APD restitution curve associated with 
all-or-none repolarization. As noted earlier, the APD restitution curve reflects an input-
output relationship, in which the preceding DI determines the APD for the next beat, but the 
APD of the next beat determines the next DI, and so forth. When a pacing rate is such that 
the DI falls in the steeply-sloped region, very small changes in DI cause large changes in 
APD (i.e. AP’s with and without domes), which then feed back to cause large changes in DI. 
Thus, at a constant heart rate, some AP’s will have prominent AP domes while others will 
exhibit very short AP’s without domes. Depending on the range of DIs visited, this can 
produce APD alternans or higher order periodicities, similar to EAD-mediated APD 
behavior associated with the EAD restitution curve in Fig. 2B. The AP domes can also 
appear irregularly in a chaotic pattern at some heart rates. The dynamic mechanisms 
underlying the chaotic pattern of AP domes are still under investigation. However, because 
chaos is present, the same scenario of regional chaos synchronization described for EADs in 
the setting of reduced repolarization (section 3.2) also applies to AP domes in the setting of 
excessive repolarization. In regions in which a critical percentage of myocytes are poised to 
have an AP with a dome, all of the myocytes in that region will be forced by electrotonic 
coupling to exhibit an AP with a dome. However, in regions below that critical percentage, 
all of the myocytes will be forced to have a short AP without a dome. The chaotic behavior 
of the AP dome is critical, because some regions will fall below the percentage of myocytes 
required for an AP dome, while other regions fall above this threshold. The result is the 
formation of islands of myocytes all exhibiting AP domes, separated by regions with very 
short APD due to all-or-none repolarization (Fig. 2C). Similar to EAD islands, the size of 
the AP dome regions depends on the violence of the chaos (tending to create voltage 
differences) versus the strength of electronic coupling (tending to smooth voltage 
differences). On each beat, the pattern changes (Fig. 2C). The result is marked dynamically-
generated dispersion of refractoriness.
When the AP dome within an island becomes large enough, the dome may propagate into 
adjacent repolarized tissue, decrementally at first, and then regeneratively for larger domes. 
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When the AP dome propagates decrementally, the local electrogram will exhibit late 
potentials following the initial voltage deflection. In patients with BS, these late potentials 
have been interpreted by some investigators to represent slow conduction due to localized 
fibrosis in the right ventricular epicardium. This interpretation has led to an alternative 
“depolarization” hypothesis that slow conduction is the most important factor promoting 
initiation of reentry [100], rather than the “repolarization hypothesis” of phase 2 reentry 
[97]. Ablating these sites has been shown to prevent arrhythmias in some of these patients. 
Imaging techniques do not currently have sufficient resolution to detect regions of fibrosis, 
which may be microscopic rather than macroscopic, in these patients. Therefore, validation 
of this alternative hypothesis will require improvements in imaging techniques or 
histological analysis at autopsy. One possibility that might explain both observations is that 
areas which chronically repolarize early would also begin to relax shortly after excitation 
and then be stretched by the surrounding tissue with normal APD that is still contracting. 
The systolic stretching might activate signaling pathways involved in electrical and 
structural remodeling, promoting fibrosis and slow conduction in these areas, as has been 
documented for electrical remodeling at late-activated sites in pacing studies [101]. In this 
case, phase 2 reentry and slow conduction might interact synergistically to promote 
arrhythmias, explaining why ablation of these regions can be therapeutically effective in 
some patients with BS. At the present time, however, this scenario is purely speculative.
When the AP dome becomes large enough to propagate regeneratively, the consequence is a 
PVC with a short coupling interval that may initiate phase 2 reentry by the following 
scenario [97]. As the AP propagates unidirectionally into the adjacent repolarized tissue, it 
can reenter the AP dome region after it has repolarized to induce reentry (illustrated in beat 
#1, Fig. 2C). Alternatively, the triggered AP can propagate unidirectionally until it 
encounters an adjacent AP dome island which has not yet repolarized. If the APD gradient is 
steep enough, wavebreak can result, initiating reentry (illustrated in beat #2 in Fig. 2C). 
Because real cardiac tissue is heterogeneous, further experimental studies are required to 
determine whether the AP dome islands are primarily due to pre-existing heterogeneous Ito 
distribution in ventricular epicardium (in which case the islands should be stationary from 
one beat to the next) or due to chaos synchronization of AP domes (in which case the island 
should change location from beat to beat). This is currently an area of active investigation.
When wavebreak due to phase 2 reentry occurs and initiates a rotor, the wavefront 
propagates via INa and therefore is very rapid (in the 10 Hz range). The arrhythmia is likely 
to manifest as a closely-coupled PVC initiating brief polymorphic VT which then either 
spontaneously terminates (if the core of the rotor drifts to a tissue boundary and 
extinguishes), or degenerates into multiple wavelet or mother rotor VF depending on the 
tissue dynamics. This corresponds to the classic pattern of idiopathic VF initiated by a 
closely-coupled PVC observed clinically in BS and SQT syndromes as well as acute 
ischemia.
Thus, the same process of regional chaos synchronization that underlies EAD-mediated 
arrhythmias is likely to be important in the setting of excess repolarization. The main 
difference is that with reduced repolarization, the chaotic behavior of EADs creates islands 
with long APD (due to EADs) next to regions with normal APD (Fig. 2B), whereas with 
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excess repolarization, the chaotic behavior of all-or-none repolarization creates islands with 
normal APD (due to AP domes) next to regions with short APD (Fig. 2C). Both scenarios 
result in marked dispersion of refractoriness.
Finally, excess repolarization can also result in late phase 3 EADs by a mechanism that does 
not necessarily involve Ito-induced all-or-none repolarization. Late phase 3 EADs have been 
observed when the duration of the Ca transient markedly outlasts the duration of the AP. 
The Ca transient duration is mostly determined by the rate of reuptake of cytoplasmic Ca 
back into the SR by the SERCA pump. If the AP is short enough to fully repolarize while 
cytoplasmic Ca remains elevated, inward INCX can delay full repolarization, allowing INa 
and/or ICa,L to recover from inactivation sufficiently to trigger another AP. This 
phenomenon was first observed in atrial pulmonary vein myocytes [102], but has been 
observed in ventricular tissue as well [103]. Whether these EADs exhibit chaotic behavior 
has not been determined, and therefore the role of chaos synchronization in promoting 
arrhythmias by this mechanism is uncertain and will require further experimental and 
modeling studies.
Dynamic factors/targets—Similar to EADs, the main dynamic factor regulating all-or-
none repolarization at the cellular level is embodied in the steeply-sloped region of the APD 
restitution curve (Fig. 2C). This region corresponds to the DI at which Ito becomes large 
enough to overcome inward currents and induce all-or-none repolarization (Fig. 2C), 
causing the AP dome to appear irregularly [104, 105]. Unlike the reduced repolarization 
reserve case in which chaotic behavior can be directly predicted from a cobweb diagram of 
the APD restitution curve [15], however, the mechanism of chaotic all-or-none 
repolarization behavior is more complex and not yet fully understood. Several mechanisms 
appear to be at play, depending on the properties of the Ito current, which varies in different 
regions of the heart and in different species. The dynamic target, however, is the same – 
suppressing the steeply-sloped region in the APD restitution curve. In principle, this is 
predicted not only to prevent all-or-none repolarization at the cellular scale, but also to 
prevent chaos synchronization from forming islands with AP domes generating phase 2 
reentry at the tissue scale.
Molecular factors/biological targets—All-or-none repolarization depends on lowering 
the voltage following the AP upstroke to a range which delays the activation of ICa,L 
sufficiently to prevent the formation of a normal AP plateau. Below this voltage threshold, 
inward current is insufficient to prevent full repolarization. Above this threshold, ICa,L 
grows slowly but regeneratively, forming the AP dome. This feature is observed in the APD 
restitution curve in Fig. 2C. At short DI, Ito has not had sufficient time to recover from 
inactivation, and the APD is normal. As the DI increases, however, Ito amplitude grows 
progressively due to its more complete recovery from inactivation. A key feature is that just 
before Ito grows large enough to induce sudden all-or-none repolarization, its effect at the 
lowering of voltage during the early plateau delays the activation of IKs, which causes the 
APD to prolong immediately prior to the onset of all-or-none repolarization [106, 107]. This 
accentuated APD prolongation is associated with a prolonged upstroke (+dV/dt phase) of the 
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AP dome that propagates similar to an EAD and plays a critical role in inducing phase 2 
reentry at the tissue level [108].
From these considerations, the molecular factor that offers the most direct biological target 
to prevent phase 2 reentry is Ito. Complete block of Ito should eliminate phase 2 reentry. A 
caveat, however, should be noted. If only partial block of Ito is achieved, this may be 
sufficient to prevent phase 2 reentry, but might increase the risk of EAD-mediated 
arrhythmias (see above). Also, phase 3 EADs that are independent of Ito would not be 
impacted by Ito blockade. Restoring Ito has been suggested as a therapeutic target in heart 
failure, in which Ito is down-regulated. However, the reduced repolarization in heart failure 
also involves down-regulation of IK1 and IKs, upregulation of INCX and increased late INa 
[54]. Selective upregulation of Ito in this setting would only partially correct the defect in 
reduced repolarization, and could make the heart susceptible to phase 2 reentry, especially if 
acute ischemia is superimposed upon heart failure, as in ischemic cardiomyopathy.
Enhancing INa or ICa,L to suppress all-or-none repolarization would also require precise 
titration in order to avoid converting excess repolarization to reduced repolarization with 
increased risk of EAD-mediated arrhythmias. There is also the risk that in heterogeneous 
cardiac tissue, enhancing INa or ICa,L to improve slow conduction in some regions might 
convert previously non-conducting regions into slow conducting regions and unmask new 
circuits capable of sustaining reentry.
Other K currents also require further study to evaluate their potential as biological targets. 
The apamin-senstive small Ca-activated K current (ISK) has been shown to be upregulated in 
heart failure, which may partially compensate for the alterations in various other currents 
that reduce overall repolarization reserve. However, both pro- and anti-arrhythmic effects of 
ISK blockade have been reported in failing hearts [109].
Fixed factors can also be biological targets for arrhythmias in this category. For example, 
the heterogeneous distribution of Ito in the right ventricle promotes phase 2 reentry in BS 
[97], as does fibrosis by promoting slow conduction and conduction block [100].
4. Linking Molecular Factors to Dynamic and Fixed Factors
In Table 1, each primary arrhythmia dynamics category (Ca cycling instability, reduced 
repolarization reserve and excessive repolarization reserve) is exemplified by a class of 
genetic channelopathies (CPVT, LQT syndromes, and BS/ERS/SQT syndromes, 
respectively). Depending on the specific mutation involved, some congenital 
channelopathies may span more than one primary arrhythmia dynamics category. The 
common clinical diseases causing the majority of ventricular arrhythmias, such as heart 
failure and ischemia, also represent mixtures of the primary categories. To develop a 
successful antiarrhythmic strategy, biological targets that suppress arrhythmia dynamics in 
one category must not exacerbate arrhythmia dynamics in the other categories, or impair 
normal cardiac function. This is particularly important when the clinical condition 
predisposing to ventricular arrhythmias spans more than one primary category.
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Another way to visualize the interaction between the three dynamics-based arrhythmia 
categories is illustrated by the graph in Fig. 4A, in which Ca cycling instability is plotted 
along the vertical axis and repolarization on the horizontal axis. This graph introduces the 
concept of parameter space, which is used in dynamics to segregate different behaviors into 
distinct regions of parameter combinations, where each relevant parameter is represented by 
a separate axis. Any combination of molecular factors which collectively produce a 
particular level (parameter value) of repolarization and a particular level (parameter value) 
of Ca cycling instability can be represented by a point (x,y) on this two-dimensional graph. 
Normal cardiac function falls in the central region in which both repolarization reserve and 
Ca cycling are in the physiologically normal ranges. Classic CPVT occupies the region in 
which Ca cycling is unstable, but repolarization is normal. Classic LQT syndromes fall in 
the region with stable Ca cycling but reduced repolarization. Classic BS/ERS/SQT 
syndromes fall in the region with stable Ca cycling but excess repolarization. Heart failure 
and acute ischemia exhibit features of both unstable Ca cycling and abnormal repolarization, 
and so occupy their own distinct regions in this parameter space (upper left and upper right, 
respectively). The hypothetical boundaries between these different parameter regions are 
indicated by dashed lines as a simplification, because the boundaries are more likely to be 
nonuniform gradients rather than distinct straight lines.
Graphically, the arrhythmia risk profile of a patient can be represented as a trajectory in this 
parameter space. Over a 24 hour period, levels of repolarization and Ca cycling instability 
vary continuously in response to the daily activities of living such as exercise, emotional 
stress, eating and sleeping, and changing environmental conditions such as temperature, 
electrolyte balance, drugs, etc. At a given point in time, each parameter combination can be 
represented by a point on the graph, defining a trajectory that wanders through this 
parameter space during the course of the day. The trajectory varies from day to day 
depending on the environmental factors encountered, but generally remains within a 
bounded region in this parameter space. Thus, in a healthy person, the trajectory stays within 
the normal region, whereas in a person with heart disease, the trajectory can wander into 
other regions in which the probability of a potentially lethal ventricular arrhythmia 
increases.
For example, in a heart failure patient in which electrical remodeling and post-translational 
signaling have reduced repolarization and destabilized Ca cycling, the trajectory may 
wander from the normal region to visit the upper right region in response to changing 
environmental conditions such as stress or exercise or hypokalemia, placing them at 
increased risk for a lethal ventricular arrhythmia (black trace). Treatment with a beta blocker 
confines the trajectory to a more restricted region by eliminating parameter combinations 
associated high levels of sympathetic activation, thereby reducing the time spent in 
dangerous parameter space regions, as illustrated in Fig. 4A (red trace). In contrast, 
treatment of the same patient with a Class III antiarrhythmic drug such as the IKr-blocker D-
sotalol would further reduce repolarization, shift the trajectory to the left and increasing the 
time spent in dangerous regions (green trace). As another example, the trajectory of a patient 
with ischemia heart disease might visit the upper right region during an anginal episode, 
which could also be potentially avoided by effective antianginal therapy with a beta blocker.
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The therapeutic goal of antiarrhythmic therapy, then, is to prevent a patient’s trajectory from 
crossing into these high risk regions of parameter space. Beta blockers accomplish this by 
reducing the dynamic responsiveness to sympathetic activation, whereas other drugs may 
accomplish this by altering different molecular factors that restore normal repolarization 
and/or Ca cycling stability. Pro-arrhythmic effects occur when an intervention that restricts 
entry into one dangerous region inadvertently facilitates entry into another dangerous region.
To incorporate fixed factors that increase electrical dispersion, such as pre-existing 
structural and electrophysiological heterogeneity, into the conceptual framework, we can 
add a third axis to reflect the aggregate level of structural and electrical heterogeneity 
throughout the tissue (Fig. 4B). In our view, fixed factors increasing electrical dispersion do 
not directly cause arrhythmias. Rather, they sensitize the heart to arrhythmias by reducing 
the level of dynamic instability required to initiate arrhythmias. For example, tissue fibrosis 
(structural remodeling) markedly alters the source-sink relationship to facilitate the 
emergence of triggers such as EADs and DADs, as well as promote slow conduction by 
reducing gap junction coupling (for review see [26]). However, the process that generates 
the trigger that initiates reentry in the region of slow conduction is a dynamic process. Thus, 
the general effect of fixed factors is to expand the arrhythmogenic regions in parameter 
space so that they encroach upon and shrink the normal region, as illustrated in Fig. 4B. In 
other words, fixed factors increasing electrical dispersion make the tissue more vulnerable to 
the emergence of triggers and initiation of reentry by dynamic factors. Thus, the daily 
trajectory through this parameter space in a patient with a structurally and electrically 
normally heart may never wander outside of the normal region, whereas the same daily 
trajectory in a patient with a structurally and electrically abnormal heart take them into high 
risk arrhythmogenic regions, as illustrated by the black traces in Fig. 4B.
Within this conceptual framework, there are three general strategies to reduce arrhythmia 
risk. The first is to expand the normal region so that the patient’s trajectory does not wander 
outside of the normal region during the course of the day. For example, in the case of a 
damaged heart in which fixed factors increasing electrical dispersion have lowered the 
threshold of dynamic instability required to induce arrhythmias, reversing pre-existing 
structural and electrical heterogeneities (i.e. moving back to the normal region along the 
third axis in Fig. 4B) will restore the low-risk region to its previously larger normal range. 
The same daily trajectory may then no longer enter the high risk arrhythmia regions. 
Interventions which reverse fibrosis would fall into this class. For example, the anti-fibrotic 
effects of ACE inhibitors might contribute to their protective effects against sudden cardiac 
death in heart failure by this mechanism.
The second general strategy is to restrict the patient’s daily trajectory in parameter space, so 
that the trajectory remains within the boundaries of the low risk region. For example, beta 
blockers and antianginal agents fall into this class, as illustrated by the red trajectory in Fig. 
4A. The third strategy is to reposition the patient’s trajectory so that it is more centrally 
located in the low risk region. In this case, the same level of excursion of the trajectory may 
no longer cross into the high risk regions. For example, in a patient with LQT3 syndrome 
caused by defective INa inactivation, a late INa blocker would move their trajectory into the 
low risk region by increasing repolarization from the reduced into the normal range.
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5. Developing an in silico drug-testing strategy
How does the dynamic state in parameter space illustrated in Fig. 4 relate to the actual 
molecular state of a patient? The molecular state of a patient can also be displayed on a 
graph, in which each molecular factor, such as the state of each ion channel and transporter, 
ion concentration, drug concentration, metabolic state, etc., is represented along a separate 
axis (Fig. 5). These molecular parameters also change continuously over the course of each 
day, tracing a trajectory through this very high dimensional parameter space with thousands 
of dimensions instead of just two. The challenge, then, is to create a map that links the high-
dimensional parameter space to the low-dimensional parameter space – that is, to define 
which combinations of molecular parameter values correspond to which aggregate dynamic 
parameter combinations of repolarization state and Ca cycling instability. If this can be 
achieved, then in principle one can predict systematically how a molecular intervention will 
impact all of the relevant dynamic factors, in all three categories of arrhythmia dynamics. A 
molecular factor could be profiled to define its potential antiarrhythmic and proarrhythmic 
actions, as well as its effects on normal excitation-contraction coupling.
Is this a wild fantasy, or a realistic possibility? Already, the U.S. Federal Drug 
Administration is exploring the modeling-based approaches for preclinical assessment of 
drug cardiotoxicity [110]. As computational power has increased and computational 
approaches to explore high dimensional parameter spaces have become more sophisticated 
[13, 14], in silico drug testing to link drug effects at the molecular level to arrhythmogenic 
cellular and tissue properties has become increasingly feasible [111, 112]. In addition, 
dimension reduction techniques have been developed to condense high dimensional 
information systems into more tractable low dimensional representations for a range of ‘big 
data’ applications [113]. One approach might be to create a panel of detailed multi-scale 
models that integrate behaviors at the subcellular, cellular and tissue levels to represent the 
different behaviors in each arrhythmia dynamics category. For example, a thousand or more 
detailed models with different molecular parameter settings could be generated to represent 
each of the six normal and arrhythmogenic parameter regions in Fig. 4A spanning a range of 
organism-scale physiological conditions (autonomic tone, electrolyte values, etc). To screen 
a molecular factor as a potential biological target in silico, the molecular intervention could 
be implemented in each of these models, and the effects on the dynamic factors regulating 
arrhythmias in each category assessed.
This approach has several conceptual advantages. First, it automatically provides a balanced 
evaluation of both anti- and pro-arrhythmic effects of a molecular intervention across the 
full spectrum of arrhythmia dynamics categories as well as normal cardiac function. Second, 
the effects of a molecular intervention are assessed on populations of models [13, 14], 
emulating the genetic and environmental diversity encountered in human populations, rather 
than on a single model in each arrhythmia dynamics category. Third, in addition to human 
cardiac electrophysiology, complementary populations of models can be generated for 
nonhuman species to facilitate direct comparison and validation of in silico predictions with 
experimental findings in nonhuman arrhythmia models.
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How would this work in practice? The in silico approach could be used in two 
complementary ways. First, to facilitate drug design, the approach can be used to predict 
theoretically the ideal modifications to a molecular factor, such as the properties of an ion 
channel that will suppress arrhythmias. For example, there are many possible biophysical 
manipulations to reduce the ICa,L window current towards the goal of suppressing EAD-
mediated arrhythmias. These include shifting the voltage dependence of activation or 
inactivation, altering kinetic parameters, and reducing the non-inactivating pedestal 
component. Implementing these altered parameters in the population of models can be used 
to identify ideal parameter combinations that are most effective at suppressing EAD-
mediated arrhythmias without disturbing normal EC coupling, exacerbating Ca cycling 
instability to a level that promotes DADs and/or alternans, or altering repolarization reserve 
in a manner promoting all-or-none repolarization and phase 2 reentry. In a complementary 
fashion, the approach could be used to facilitate drug screening. Imagine that a small 
molecule drug screen identifies a compound with novel effects on the biophysical properties 
of an ion channel. For example, the compound might selectively block the late ICa,L without 
affecting the peak amplitude (analogous to ranolazine for late INa). The detailed biophysical 
properties could be implemented in the population of models to predict whether the altered 
ICa,L properties would be effective at suppressing EAD-mediated arrhythmias without 
creating the other adverse effects. Thus, as it is refined, the in silico approach could serve as 
a drug-development and screening platform both to predict ideal antiarrhythmic drug 
properties, and to evaluate drugs whose biophysical properties have already been 
experimentally characterized, prior to moving forward to costly animal models for further 
testing.
6. Application to Supraventricular Arrhythmias
Many supraventricular arrhythmias can now be effectively and permanently cured by 
catheter ablation techniques, including atrioventricular reentrant tachycardia, atrioventricular 
nodal reentrant tachycardia, atrial tachycardia and atrial flutter. The most challenging, 
however, remains atrial fibrillation (AF). AF mechanisms are still controversial, in part 
because of the greater structural and electrophysiological complexity of the atria and its 
associated structures including the sinus and atrioventricular nodes, venae cavae, pulmonary 
veins and valvular annuli. AF is also the most common sustained arrhythmia, affecting 5–
10% of the population over the age of 70 [114] and accounting for a quarter of 
cerebrovascular accidents (strokes) in the elderly. Under the most favorable conditions 
(paroxysmal atrial fibrillation in structurally normal hearts), the current success rate of 
ablation is around 70%, and under 50% for long-standing persistent AF in patients with 
enlarged atria or heart failure [115]. Repeat ablations are often necessary, and each 
procedure carries a 5% risk of significant complications [116]. Thus, as with ventricular 
arrhythmias, development of effective pharmacologic/biologic therapy for AF is highly 
desirable.
Although the dynamics-based classification in Table 1 focuses on ventricular arrhythmias, 
the same approach can be adapted to supraventricular arrhythmias and AF, once the key 
dynamic mechanisms have been appropriately defined. There is no reason to believe that the 
dynamic mechanisms outlined in Table 1 are not also applicable to the atria. DADs, DAD-
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mediated trigger activity [117] and spatially discordant alternans [118] have been described 
in atrial tissue, as have EADs and EADmediated triggered activity [102]. In addition, 
evidence of both multiple wavelet and mother rotor fibrillation have been presented in atria 
(for review see [119]). Excessive repolarization reserve caused by gain-of-function K 
channel mutations has also been associated with familial AF [96]. Direct experimental 
evidence for chaos synchronization, biexcitability and phase-2 reentry in atrial tissue, 
however, has yet to be obtained. Is AF driven by fundamentally different mechanisms than 
VF? Unlike VF, which is lethal if not immediately defibrillated, atrial fibrillation is usually 
tolerated hemodynamically, so that its dynamical mechanisms may evolve over time as 
electrical and structural remodeling develop. For example, paroxysmal AF in normal sized 
atria may initially be related to triggers emanating from the pulmonary veins and/or other 
venous structures, caused by localized focal activity or microreentry which initiates 
nonsustained multiple wavelet or mother rotor fibrillation. This would account for the 
reasonably high success rate of ablation at this stage. However, as AF becomes persistent 
and long-lasting, the underlying electrical and structural remodeling may alter the tissue 
substrate sufficiently to allow multiple wavelet or mother rotor fibrillation to continue 
indefinitely [120], so that isolation of triggers is no longer effective. Enlarged atria due to 
valvular disease or diastolic ventricular dysfunction may also fall into the latter category due 
to electrical and structural remodeling induced by chronic hemodynamic stress.
7. Summary and Challenges
Our goal has been to illustrate how molecular factors interact with dynamic and fixed factors 
at the subcellular, cellular and tissue and organism scales to cause ventricular arrhythmias. 
Achieving a thorough understanding of these interactions is critical for developing novel 
effective pharmacologic/biologic therapies for cardiac arrhythmias. Pharmacologic/biologic 
targets are molecular factors, but arrhythmias are determined by dynamic factors at the 
subcellular, cellular, tissue and organism scales interacting with fixed factors increasing 
electrical dispersion at the tissue scale. The highest risk of arrhythmias arises when dynamic 
factors, interacting with fixed factors, simultaneously promote the emergence of triggers 
while enhancing electrical dispersion within the tissue. The proposed dynamics-based 
classification outlined in Table 1 represents an attempt to synthesize what is currently 
known about these relationships. Accordingly, we have classified ventricular arrhythmias 
into three major dynamic categories relating to unstable Ca cycling, reduced repolarization 
and excess repolarization. Each of these primary categories is represented by a group of 
inherited channelopathies (CPVT, LQT syndrome and BS/ERS/SQT syndrome, 
respectively). In addition, the more common causes of ventricular arrhythmias, heart failure 
and ischemia, represent mixtures of the primary categories. We have summarized the current 
state-of-knowledge about the dynamic factors operating at the subcellular, cellular, tissue 
and organism scales relevant to each arrhythmia dynamics category, and provided 
illustrative examples of how these dynamic factors can be related to molecular factors.
To illustrate conceptually how these arrhythmia dynamics might apply to a patient at 
increased risk of ventricular arrhythmias, we presented the parameter space concept (Fig. 4). 
We envision the patient as wandering through this parameter space during the course of their 
daily activities, defining a trajectory. The trajectory of a healthy person with a normal heart 
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does not wander outside of the normal region, whereas the trajectory of a patient with 
congenital or acquired heart disease crosses into the abnormal regions, placing them at 
increased risk of a ventricular arrhythmia. In this representation, the goal of pharmacologic/
biologic antiarrhythmic therapy is to prevent a patient’s trajectory from wandering outside 
of the normal region (Fig. 4A). In principle, this can be accomplished by one of three 
strategies: 1) expanding the normal region by reversing fixed factors that make the heart 
more sensitive to dynamic instability (e.g. reversing fibrosis in heart failure); 2) reducing the 
extent to which the trajectory wanders (e.g. beta blocker therapy in ischemia); or 3) re-
centering the trajectory in the normal region (e.g. late INa blocker drugs to correct the defect 
in LQT3 syndrome). The great challenge will be to create an accurate map that links the low 
dimensional parameter space of dynamic factors to the high dimensional parameter space of 
molecular factors, using computational methods and dimensional reduction analytics (Fig. 
5). If successful, this endeavor has the potential to provide a systematic approach to evaluate 
and predict in silico how molecular factors, such as altered biophysical properties of an ion 
channel, affect not only the targeted arrhythmia category, but all of the other relevant 
arrhythmia categories as well as normal cardiac EC coupling. Efficacy and safety will be 
addressed simultaneously. May the journey begin!
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Abbreviations
AP action potential
APD AP duration
BS Brugada syndrome
CaMKII Ca-calmodulin kinase II
CPVT catecholaminergic polymorphic ventricular tachycardia
CV conduction velocity
DAD delayed afterdepolarization
EAD early afterdepolarization
ERS early repolarization syndrome
ICD implantable cardioverter-defibrillator
ICa, L L-type Ca current
IKr rapid component of the delayed rectifier K current
IKs slow component of the delayed rectifier K current
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INa Na current
Ito transient outward K current
LQT long QT
NCX Na-Ca exchanger
PVC premature ventricular complex
RyR ryanodine receptor
SERCA sarco-endoplasmic reticulum Ca ATPase
SQT short QT
SR sarcoplasmic reticulum
VF ventricular fibrillation
VT ventricular tachycardia
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Highlights
• We group ventricular arrhythmias into three categories based on their 
underlying dynamics
• The Ca cycling instability group includes CPVT, heart failure and ischemia
• The reduced repolarization group includes long QT syndromes and heart failure
• The excessive repolarization reserve group includes J wave syndromes and 
ischemia
• Strategies to link arrhythmogenic dynamic factors to molecular targets are 
proposed
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Fig. 1. 
A. The cause versus the mechanism of an arrhythmia. A molecular factor, such as a 
genetic mutation that alters a protein’s function, can unequivocally be the cause of an 
arrhythmia, but does not directly define the mechanism. The mechanism of the arrhythmia is 
defined by the effects of the molecular factor on the dynamic factors and fixed factors at 
each increasingly integrated scale. B. Fixed factors which increase electrical dispersion 
decrease the threshold of dynamic instability at which arrhythmias occur. Dynamic 
factors creating dynamic instability (dark shading) jointly increase the probability of triggers 
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(left oval) and tissue vulnerability (right oval), whose overlap defines the arrhythmia zone 
(red). Fixed factors that increase structural and electrophysiological heterogeneity act 
synergistically with dynamic factors to promote triggers and increase vulnerability, 
widening the arrhythmia zone.
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Fig. 2. Trigger-substrate interactions initiating reentry
A. Spatially discordant alternans: steep SR Ca release relationship and/or steep APD 
restitution coupled with conduction velocity (CV) restitution causes APD alternate on a 
short-long (blue-red) pattern in one region and long-short (red-blue) in another region, 
separated by a nodal line where APD does not alternate (white). The pattern in beat #1 
reverses in beat #2. In beat #2, a DAD arising from the short APD region triggers a PVC (★) 
which blocks superiorly (dashed line) but conducts laterally (solid lines), initiating reentry. 
B. EAD chaos synchronization: steep EAD restitution causes EADs to occur chaotically 
from beat-to-beat. In tissue, electrotonic coupling causes regional chaos synchronization to 
generate EAD islands (red regions), separated by regions without EADs (blue), whose 
position and size vary from beat-to-beat. Beat #1 illustrates a scenario in which a triggered 
PVC (★) arising from an EAD island blocks superiorly (dashed line) but conducts inferiorly 
(solid line), subsequently reentering the blocked region to induce reentry. Beat #2 illustrates 
a scenario in which the triggered PVC arising from an EAD island encounters another EAD 
island, resulting in conduction block (dashed line) and reentry (solid lines). C. AP dome 
chaos synchronization: steep AP dome restitution causes AP domes to appear chaotically 
from beat-to-beat. In tissue, electrotonic coupling causes regional chaos synchronization to 
generate AP dome islands (red regions), separated by regions with very short APD due to 
all-or-none repolarization (blue regions), whose position and size vary from beat-to-beat. An 
AP dome (★) propagating into the short APD region induces phase 2 reentry. In tissue, 
electrotonic coupling causes regional chaos synchronization to generate AP dome islands 
(red regions), separated by regions with very short APD due to all-or-none repolarization 
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(blue), whose position and size varies from beat-to-beat. Beat #1 illustrates a scenario in 
which an AP dome (★) propagating out of an island blocks inferiorly (dashed line) but 
conducts laterally (solid line), subsequently reentering the blocked region to induce phase 2 
reentry. Beat #2 illustrates a scenario in which the propagating AP dome (*) encounters 
another AP dome region that is still refractory, resulting in conduction block (dashed line) 
and reentry (solid lines).
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Fig. 3. The L-type Ca window current and EADs
A. A rabbit ventricular myocyte was exposed to hypokalemia (2.7 mM) to induce EADs, 
after which the endogenous L-type Ca current (ICa,L) was pharmacologically blocked and 
replaced with a virtual ICa,L using the dynamic clamp technique, which reconstituted the 
EADs (blue trace). B. Shifting the ICa,L half-maximal activation voltage from −1 mV (blue 
curve) to +4 mV (black curve) to reduce the overlap between the steady state activation (SS 
Act) and inactivation (SS Inact) curves defining the ICa,L window current region (blue-
hatched area) suppressed EADs and restored APD to normal (black trace in A). C. Summary 
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results from 3 myocytes, showing that APD was restored from >2 s (with EADs present in 
80% of action potentials) to < 0.5 s (with 0% EADs present). (Adapted from Madhvani et al 
[93], with permission).
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Fig. 4. Parameter space representation of arrhythmia dynamics
A. Two-dimensional representation. The vertical axis represents the aggregate state of Ca 
cycling varying from stable to unstable, and the horizontal axis the aggregate state of 
repolarization from reduced to excessive. The white region represents the normal heart, and 
various combinations of Ca cycling instability and reduced or excess repolarization define 
the colored regions corresponding to CPVT, LQTS, BS/ERS/SQTS, HF and ischemia (Isc). 
The black line indicates the hypothetical daily trajectory in parameter space of a patient with 
heart failure which episodically leaves the normal region and enters high risk arrhythmia 
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regions. The red trajectory shows the same patient after treatment with a beta blocker to 
confine the trajectory to the white region (i.e. lower arrhythmia risk) by blunting excessive 
sympathetic activation. The green trajectory shows the heart failure patient treated with a 
Class III antiarrhythmic drug (K channel blocker) that further reduces repolarization reserve, 
increasing arrhythmia risk. B. Three-dimensional representation of arrhythmia parameter 
space incorporated fixed factors which increase electrical dispersion. A third axis has been 
added, corresponding to the aggregate state of fixed factors (pre-existing heterogeneities 
related to electrical and structural remodeling, etc) which increase electrical dispersion and 
lower the threshold for unstable Ca cycling and abnormal repolarization required to cause 
ventricular arrhythmias. This has the effect of shrinking the low risk white region and 
expanding the high arrhythmia risk colored regions, such that the same daily trajectory 
(black line) now enters the high risk regions.
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Fig. 5. Linking dynamic factors to molecular factors
The aggregate dynamic parameters in the low dimensional parameter space defining 
arrhythmia risk (left) are ultimately determined by the interactions between molecular 
factors in a much higher dimensional parameter space (right) in which each molecular factor 
(e.g. properties of an ion channel) is represented by its own axis. The ultimate goal is to 
create a map that links the high dimensional space to the low dimensional space, allowing 
molecular factors to be evaluated as biological targets to lower arrhythmia risk.
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